Drug intelligence / Profile preview

birth control + Brevail

Development stage
Unknown
Lead developer
Barleans
Modality
Small Molecules
Administration
Oral
01

Overview

This is a non-standard combination of two products: - A pharmaceutical oral contraceptive (birth control pill), typically containing synthetic estrogen (such as ethinyl estradiol) and progestin (such as norethindrone), used for the prevention of pregnancy. These agents work primarily by inhibiting ovulation, thickening cervical mucus to prevent sperm penetration, and altering the endometrial lining to reduce the likelihood of implantation[2][3][5][6]. - Brevail is a dietary supplement made from standardized flaxseed lignan extract (primarily secoisolariciresinol diglucoside) and sometimes vitamin D3. It is marketed for supporting balanced estrogen metabolism, breast health, and relief from menopausal or PMS symptoms. The mechanism involves providing plant lignans that may modulate estrogen activity in the body[1][4][7]. There are no approved pharmaceutical products combining these two agents into a single formulation; this refers to concurrent use.

Brand names
Brevail
Other names
Brevail in PCOSoral contraceptive plus flaxseed lignanoral contraceptive plus secoisolariciresinol diglucoside
02

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on birth control + Brevail.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on birth control + Brevail.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call